Navigation Links
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Date:3/13/2009

in Peripheral T-Cell Lymphomas Overexpressing Activated Syk" suggested that Syk may play a critical role in some PTCLs and represents a feasible therapeutic target for further clinical study.

Phase 2 Design

The Phase 2 trial will be conducted in two stages at several centers in North America with each patient receiving 200mg of R788 twice a day for a minimum of 8 weeks, or until disease progression or withdrawal from the trial. During stage one, 19 men and women with PTCL who have previously failed to respond to standard of care treatment for their disease are expected to be evaluated. Stage two is expected to include the enrollment of approximately 36 patients. Efficacy will be assessed by CT/PET scans at baseline and CT scans of the disease-involved areas at 8 weeks. Safety will be assessed by periodic physical exams, blood tests and clinical laboratory work, among others. Results of the clinical trial are expected in the second half of 2010.

In June 2008, Rigel first reported results of a Phase 2 clinical trial of R788 in the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphomas. R788 was well-tolerated in this patient population and showed therapeutic benefit in patients suffering from certain subcategories of the disease, especially small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and diffuse large B-cell lymphoma. More details about the outcome of that clinical trial and the role that Syk inhibition may play in the treatment of lymphoma patients can be found at Rigel's website, http://www.rigel.com/rigel/lymphoma.

About Rigel

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intrace
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
3. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
4. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
8. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
9. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
10. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 InspireMD, Inc. ("InspireMD" ... in embolic protection stents, today announced new 6-month ... Elevation Reperfusion) trial demonstrating that the MGuard Embolic ... eluting stents in all-cause mortality in ST segment ... trial were presented at the InspireMD STEMI Symposium ...
(Date:5/23/2013)... and PARIS , May 23, ... a leading developer and manufacturer of precision guided therapy ... coronary and peripheral vascular disease, today announced preliminary results ... I ndependent S tenosis E valuation) ... trial session at EuroPCR 2013. These prospective results confirm ...
(Date:5/23/2013)... 22. Mai 2013 Ranbaxy ... Tochtergesellschaft von Daiichi Sankyo Co., Ltd. ... 22. Mai die Maßnahmen bekannt, die ... hat, um sich der Angelegenheiten der ... http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html ). Daiichi Sankyo ...
Breaking Medicine Technology:InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2
... , July 27 BioElectronics Corp. (Pink Sheets: ... its distribution partner for Japan , YesDTC Holdings, Inc. ... staff of the pending review by Japanese government medical device ... review will take place on Wednesday, July 28th . ...
... , July 27 Codexis, Inc. (Nasdaq: CDXS ) today ... Leadership Forum, August 8-10, 2010 in Vail, CO. ... presentation on August 10 at 8:30 am Mountain Time . ... www.codexis.com .   , , ...
Cached Medicine Technology:BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date 2Codexis to Present at the Pacific Crest Technology Leadership Forum 2
(Date:5/23/2013)... Netsmart today announced it is ranked ... information technology (HIT) providers for 2013. , The HCI 100 ... Healthcare Informatics magazine. Netsmart’s ranking of #49 is up ... growth is largely due to our commitment to helping organizations ... where resources are scarce, the demand for care is unprecedented ...
(Date:5/23/2013)... 2013 Applied PilotFish Healthcare Integration ... it has added support for the Direct Protocol to ... for Healthcare. In addition to the product’s already included ... and Web Services, it now offers support for the ... a specification of the Direct Project and ...
(Date:5/23/2013)... May 23, 2013 Aero Fulfillment Services, ... selected by NewWave Biosciences to be the sole fulfillment ... care professionals. , Brad Cole, CEO New Wave ... reasons including their central location, e-commerce experience with both ... and overall end-to-end solution that will expand as our ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Maintaining ... today launches its Summer Health Campaign. Kicking off in ... to offering a luxury bed for everyone and to ... overall health and well-being. , May is Better Sleep ... by the Better Sleep Council due to the Centers ...
(Date:5/23/2013)... Sika Sarnafil , the worldwide market ... Imperial Roof Systems of Iowa as the Recycling Project ... quality during the re-roofing of the SuperTarget retail store ... Sarnafil Elite contractor and one of Target’s Preferred Tier ... to sustainable building practices and they are a worthy ...
Breaking Medicine News(10 mins):Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release 2Health News:NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation 2Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2
... recent research has found that pregnant womens contact with ... birth weight. ,The National Research Centre ... the study, together with colleagues from the French Institute ... GSF. ,In this study, the scientists have ...
... has justified placing Paris Hilton under house arrest by citing ... Judge Michael T Sauer who ordered her back to ... doctors. ,On Larry Kings show, Larry Waldie, who had ... didn't care, and that he even hinted that Hilton was ...
... The UN has declared Galapagos Island in danger. The ... tourism is threatening the environment that helped shape ... first place on the planet officially designated as a ... danger as booming tourism and immigration threaten giant tortoises ...
... care is taking a heavy toll in England, both in ... 189m every year , according to a report published today ... ,The report - Wasted Money, Wasted Lives - concludes ... year from epilepsy, 69,000 people are living with unnecessary seizures, ...
... need to be cautious according to new research presented for ... ,Unlike approved generic drug names, brand names of ... that a branded product in one country is the same ... in other counties. ,A new study by regulatory ...
... researchers have established that the affordable drug, Gatifloxacin, is ... ,The study was conducted by a team of ... Lalitpur in Kathmandu, Nepal. ,As part of ... drug with Cefixime, which is currently recommended by the ...
Cached Medicine News:Health News:Fine Particulate Matter from Traffic may Reduce Unborn Babies Birth Weight 2Health News:Galapagos on UN Endangered List 2Health News:Blunders in Epilepsy Care Cost Lives, and Money UK Report 2
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... Ophthalmic Products provide the ... free products for unparalleled ... cleaning of fine microsurgical ... material is highly absorbent, ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: